text: Ellagic acid attenuates bleomycin and cyclophosphamide-induced pulmonary toxicity in Wistar rats.
  Use of bleomycin (BLM) and cyclophosphamide (CP) as chemotherapeutic drugs is associated with side effects including toxicity to respiratory system. Their co-administration may enhance lung toxicity which may subsequently progress to the lung fibrosis. Natural compounds have shown mitigating effects against toxicity of anticancer drugs. Ellagic acid (EA), a polyphenolic compound present in many fruits and nuts in addition to walnut has shown promising protective effect against toxicity of drugs and chemicals. We studied the ameliorative effect of EA on lung toxicity in rats exposed to CP (150mg/kgb.w., i.p.) and BLM (10U/kgb.w., i.t.). EA (15mg/kgb.w., p.o.×14days) treatment modulated enhanced hydroxyproline level, lipid peroxidation, myeloperoxidase activity, nitric oxide production and protein carbonyl formation in lungs of rats exposed to toxic anticancer drugs. There was a marked decrease in GSH content and activities of antioxidant enzymes as a result of BLM and CP treatment. Bronchoalveolar lavage fluid showed increased level of cytotoxicity markers in drug treated animals. Treatment with EA attenuated these changes. Histopathological findings also showed protective effects of EA. In conclusion, EA emerged as a natural protectant with an ability to protect lungs from onslaught of pulmonary toxicity of anticancer drugs.
entities.id: T10 T11 T12 T13 T14 T1 T2 T3 T4 T5 T6 T7 T8 T9
entities.type: CHEMICAL CHEMICAL CHEMICAL CHEMICAL GENE-Y CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL CHEMICAL
entities.text: BLM Ellagic acid bleomycin cyclophosphamide myeloperoxidase BLM cyclophosphamide Ellagic acid BLM hydroxyproline bleomycin nitric oxide carbonyl GSH